{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:43:24Z","timestamp":1773949404512,"version":"3.50.1"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"Background<\/jats:title>Drug hypersensitivity reactions are common in pediatric hemato-oncology patients due to multiple factors including immune compromise and pharmacological complexities. Fever can signify severe delayed-type hypersensitivity reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS) or drug-induced hypersensitivity syndrome (DIHS). The etiology of fever as an isolated hypersensitivity reaction to chemotherapeutic agents not fully understood. Here, we report three children with intracranial neoplasms experiencing recurrent febrile reactions following Vinca alkaloid-based chemotherapy, mitigated by cysteinyl leukotriene receptor antagonist therapy.<\/jats:p><\/jats:sec>Methods<\/jats:title>We present a series of pediatric patients with diverse intracranial neoplasms who developed recurrent fever episodes after multiple courses of Vinca alkaloid-based chemotherapy. Treatment involved prophylactic and post-chemotherapy administration of a cysteinyl leukotriene receptor antagonist to prevent fever episodes and enable completion of chemotherapy regimens without protocol modifications or desensitization.<\/jats:p><\/jats:sec>Results<\/jats:title>All three patients experienced fever consistent with delayed-type hypersensitivity reactions to Vinca alkaloids. Prophylactic use of the leukotriene antagonist Montelukast successfully prevented fever recurrence, allowing uninterrupted completion of chemotherapy courses.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Our findings suggest that Montelukast, a leukotriene antagonist, may be beneficial in managing fever as a delayed-type hypersensitivity reaction to Vinca alkaloids in pediatric patients. Further research is warranted to elucidate the underlying mechanisms and leukotriene pathways involved in drug-induced fever reactions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2024.1361403","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T06:02:14Z","timestamp":1722924134000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug fever\u2014an immune-mediated delayed type hypersensitivity reaction to Vinca alkaloids in pediatric oncology patients, possibly mediated by cysteinyl leukotrienes"],"prefix":"10.3389","volume":"5","author":[{"given":"Mona I.","family":"Kidon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soad","family":"Haj Yahia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gadi","family":"Abebe-Campino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Agmon-Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Yelon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.iac.2022.01.001","article-title":"Pediatric drug allergy","volume":"42","author":"Prosty","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"777498","DOI":"10.3389\/fphar.2021.777498","article-title":"Adverse drug reactions in pediatric oncohematology: a systematic review","volume":"12","author":"Amaro-Hosey","year":"2021","journal-title":"Front Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1592\/phco.30.1.57","article-title":"Drug fever","volume":"30","author":"Patel","year":"2010","journal-title":"Pharmacotherapy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/BF03261972","article-title":"Drug fever: a descriptive cohort study from the French national pharmacovigilance database","volume":"35","author":"Vodovar","year":"2012","journal-title":"Drug Saf"},{"key":"B5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00520-015-2820-8","article-title":"Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4","volume":"24","author":"Ogawara","year":"2016","journal-title":"Support Care Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.tjog.2021.07.018","article-title":"Drug fever induced by carboplatin-based regimens: higher incidence in a women\u2019s hospital","volume":"60","author":"Zhang","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJMra071371","article-title":"Leukotrienes","volume":"357","author":"Peters-Golden","year":"2007","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000312669","article-title":"Cysteinyl leukotrienes and their receptors: molecular and functional characteristics","volume":"85","author":"Singh","year":"2010","journal-title":"Pharmacology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"838079","DOI":"10.3389\/fphar.2022.838079","article-title":"Inflammation and cancer: from the development of personalized indicators to novel therapeutic strategies","volume":"13","author":"Ballerini","year":"2022","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0304-3835(98)00132-3","article-title":"Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078","volume":"130","author":"Nagayama","year":"1998","journal-title":"Cancer Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/17512433.2022.2100345","article-title":"Genetic markers of drug hypersensitivity in pediatrics: current state and promise","volume":"15","author":"Elzagallaai","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1081-1206(10)60247-5","article-title":"Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization","volume":"102","author":"Breslow","year":"2009","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1361403\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T06:02:16Z","timestamp":1722924136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1361403\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":13,"alternative-id":["10.3389\/falgy.2024.1361403"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1361403","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"article-number":"1361403"}}